Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2000 Sep;44(9):2557-60.
doi: 10.1128/AAC.44.9.2557-2560.2000.

In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized

C M Bebear  1 , H Renaudin, A Charron, D Gruson, M Lefrancois, C Bebear
Affiliations
Comparative Study

In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized

C M Bebear et al. Antimicrob Agents Chemother. 2000 Sep.

Abstract

The in vitro activity of trovafloxacin against 125 strains of Mycoplasma species and Ureaplasma urealyticum, including fluoroquinolone-susceptible and fluoroquinolone-resistant species, was compared to those of other fluoroquinolones, doxycycline, and erythromycin. The MIC at which 90% of isolates are inhibited for all fluoroquinolone-susceptible strains was 0.25 microg/ml. Whatever the associated mutations, trovafloxacin exhibited greater activity than the other fluoroquinolones tested against fluoroquinolone-resistant Mycoplasma hominis and U. urealyticum isolates.

PubMed Disclaimer

References

    1. Bébéar C, Robertson J. Determination of minimal inhibitory concentration. In: Tully J G, Razin S, editors. Molecular and diagnostic procedures in mycoplasmology. II. San Diego, Calif: Academic Press, Inc.; 1996. pp. 189–199.
    1. Bébéar C M, Bové J M, Bébéar C, Renaudin J. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob Agents Chemother. 1997;41:269–273. - PMC - PubMed
    1. Bébéar C M, Renaudin H, Boudjadja A, Bébéar C. In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrob Agents Chemother. 1998;42:703–704. - PMC - PubMed
    1. Bébéar C M, Renaudin H, Charron A, Bové J M, Bébéar C, Renaudin J. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother. 1998;42:2304–2311. - PMC - PubMed
    1. Bébéar C M, Renaudin H, Schaeverbeke T, Leblanc F, Bébéar C. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas. J Antimicrob Chemother. 1999;43:711–714. - PubMed

Publication types

MeSH terms